Abstracts tagged "Decision analysis"

Abstract Number: 2778 • 2017 ACR/ARHP Annual Meeting
Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions
Mark Harrison¹, Luke Spooner², Marie Hudson³, Katherine Milbers⁴, Cheryl L. Koehn⁵, Axel Finckh⁶ and Nick Bansback⁷, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ⁴Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁵Arthritis Consumer Expert, Vancouver, BC, Canada, ⁶University Hospital of Geneva, Geneva, Switzerland, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Increasingly, evidence suggests that treatment of people at risk of rheumatoid arthritis (RA) with anti-rheumatic drugs could prevent the onset of disease. Ongoing randomized…
Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Joost Swart¹, Nico Wulffraat², Sytze de Roock³ and Pieter van Dijkhuizen⁴, ¹Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Nick Bansback^1,2, Mark Harrison³, William G Dixon⁴ and Paul Han⁵, ¹Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ⁴Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting
Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment
Monika Hifinger¹, Mickaël Hiligsmann², Sofia Ramiro³, Verity Watson⁴, Johan L. Severens⁵, Bruno Fautrel⁶, Loreto Carmona⁷, Till Uhlig⁸, Ronald van Vollenhoven⁹, Peggy Jacques¹⁰, Jacqueline Detert¹¹, Carlo Alberto Scirè¹², Florian Berghea¹³, Márta Péntek¹⁴, Jose canas Silva¹⁵, Andrew Keat¹⁶ and Annelies Boonen¹⁷, ¹Rheumatology, University of Maastricht, Maastricht, Netherlands, ²Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ⁵Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁷Instituto de Salud Musculoesqueletica, Madrid, Spain, ⁸Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ¹⁰University Hospital Ghent, Ghent, Belgium, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹²Italian Society for Rheumatology, Milan, Italy, ¹³Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ¹⁴Corvinus University of Budapest, Budapest, Hungary, ¹⁵Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ¹⁶Northwick Park Hospital, Harrow, United Kingdom, ¹⁷Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…
Abstract Number: 2312 • 2015 ACR/ARHP Annual Meeting
Patient Preferences for Total Knee Replacement Surgery: Two Year Follow-up
Ernest Vina¹, Di Ran², Erin Ashbeck², Said Ibrahim³, Michael J. Hannon⁴, Jin Zhou⁵ and C. Kent Kwoh¹, ¹Rheumatology, University of Arizona, Tucson, AZ, ²Arthritis Center, University of Arizona, Tucson, AZ, ³Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Epidemiology & Biostatistics, University of Arizona, Tucson, AZ
Background/Purpose: Patients’ preferences for total knee replacement (TKR) may determine actual receipt of TKR and may also change over time. Yet, no study has longitudinally…
Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting
Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Mark Harrison^1,2, Carlo Marra³ and Nick Bansback^4,5, ¹Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ³School of Pharmacy, Memorial University, St John's, NF, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…
Abstract Number: 2453 • 2015 ACR/ARHP Annual Meeting
Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage
Balu Athreya¹, Mary Beth Son², Jonathan S. Hausmann³, Elizabeth Ang⁴, David Zurakowski⁵, Michael Segal⁶ and Robert Sundel⁷, ¹duPont Hospital for Children/Thomas Jefferson University, Wilmington, DE, ²Division of Immunology, Children's Hospital Boston, Boston, MA, ³Rheumatology, Children's Hospital Boston, Boston, MA, ⁴Paediatrics, University Children's Medical Institute, NUH, Singapore, Singapore, ⁵Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁶SimulConsult, Chestnut Hill, MA, ⁷Immunology, Childrens Hospital, Boston, MA
Background/Purpose: This projects seeks to respond to the critical shortage of pediatric rheumatologists encapsulating the diagnostic information of the field in an advanced diagnostic decision…
Abstract Number: 779 • 2015 ACR/ARHP Annual Meeting
Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Haiyan Qu¹, Jinoos Yazdany², W. Winn Chatham³, Ricahrd Shewchuk⁴ and Jasvinder A. Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our objective was to derive a cognitive map of how stakeholders perceive patient-identified facilitators to establish a theoretical framework for the purpose of developing…
Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting
Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
Maya Gerstein¹, Roberto Ezequiel Borgia², Brian Feldman¹, Deborah M. Levy³, Sharon Sukhdeo⁴, Susanne M. Benseler⁵, Lawrence W.K. Ng¹, Mohamed Abdelhaleem⁶, Earl D. Silverman² and Linda T Hiraki⁷, ¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital For Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁶Department of Paediatric Laboratory Medicine, Division of Haematopathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…
Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting
Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²PsAID taskforce, EULAR, Zurich, Switzerland, ³2nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
Abstract Number: 2635 • 2012 ACR/ARHP Annual Meeting
Exploring the Influence of Patient Perceptions On Medication Escalation in Daily Practice
Jos Hendrikx¹, Wietske Kievit², Jaap Fransen² and Piet L.C.M. van Riel², ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: In rheumatoid arthritis (RA), patients' and physicians' perceptions of disease can differ and patients who are satisfied with their health do not tend to…
Abstract Number: 2509 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Training Rural Providers to Perform Joint Injections
Michael J. Battistone¹, Richard E. Nelson², William D. Ashworth³, Andrea Barker³, Marissa Grotzke⁴, Timothy A. Huhtala⁵, Robert Z. Tashjian⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ³General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁵Division of General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Community based outpatient clinics (CBOCs) have been established by the Department of Veteran Affairs (VA) to provide primary care services to veterans living in…
Abstract Number: 2463 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis
Josh J. Carlson¹, Sarika Ogale², Fred Dejonckheere³ and Sean Sullivan⁴, ¹Pharmacy, University of Washington, Seattle, WA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: The ADACTA trial found that biologic naïve patients with severe active RA who are methotrexate (MTX) intolerant or in whom continued MTX treatment is…
Abstract Number: 2440 • 2012 ACR/ARHP Annual Meeting
Decisional Conflict Among Vulnerable Patient Populations with Rheumatoid Arthritis Is Associated with Limited Health Literacy and Non-English Language
Laura Trupin¹, Jennifer Barton¹, Gina Evans-Young¹, John B. Imboden¹, Andrew J. Gross², Dean Schillinger³ and Edward H. Yelin⁴, ¹Rheumatology, UCSF, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine and Center for Vulnerable Populations, UCSF, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Suboptimal communication in shared decision-making among vulnerable populations has been reported in rheumatoid arthritis (RA). National and international recommendations for quality health care highlight…
Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Stéphanie Emilie¹, Cécile Gaujoux-Viala², Benjamin Granger³, Anne-Christine Rat⁴, Bernard Combe⁵ and Bruno Fautrel⁶, ¹Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, ²Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].